Company Abbott Laboratories Börse Stuttgart
Equities
ABL
US0028241000
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
94.12 EUR | +0.11% | -1.85% | -5.27% |
Jul. 08 | That's not so bad, is it? | |
Jul. 02 | Evercore ISI Adjusts Price Target on Abbott Laboratories to $120 From $125, Maintains Outperform Rating | MT |
Business Summary
- diagnostic systems and instruments (39.1%);
- vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.;
- nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products;
- medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.;
- other (15.9%).
Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Medical Devices
42.1
%
| 14,687 | 33.6 % | 16,887 | 42.1 % | +14.98% |
Diagnostic Products
24.9
%
| 16,584 | 38.0 % | 9,988 | 24.9 % | -39.77% |
Nutritional Products
20.3
%
| 7,459 | 17.1 % | 8,154 | 20.3 % | +9.32% |
Established Pharmaceutical Products
12.6
%
| 4,912 | 11.3 % | 5,066 | 12.6 % | +3.14% |
Other
0.0
%
| 11 | 0.0 % | 14 | 0.0 % | +27.27% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
38.5
%
| 18,142 | 41.6 % | 15,452 | 38.5 % | -14.83% |
All Other Countries
35.1
%
| 14,841 | 34.0 % | 14,084 | 35.1 % | -5.10% |
Germany
5.8
%
| 2,340 | 5.4 % | 2,345 | 5.8 % | +0.21% |
China
5.6
%
| 2,133 | 4.9 % | 2,253 | 5.6 % | +5.63% |
India
4.4
%
| 1,649 | 3.8 % | 1,750 | 4.4 % | +6.12% |
Switzerland
4.1
%
| 1,336 | 3.1 % | 1,638 | 4.1 % | +22.60% |
Japan
3.8
%
| 1,932 | 4.4 % | 1,513 | 3.8 % | -21.69% |
Netherlands
2.7
%
| - | - | 1,074 | 2.7 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Robert Ford
CEO | Chief Executive Officer | 50 | 14-12-31 |
Philip Boudreau
DFI | Director of Finance/CFO | 51 | 96-12-31 |
Scott House
CTO | Chief Tech/Sci/R&D Officer | - | 89-12-31 |
Melissa Brotz
IRO | Public Communications Contact | - | - |
Jim Leffelman
PRN | Corporate Officer/Principal | - | - |
Andrea Wainer
PRN | Corporate Officer/Principal | - | 96-12-31 |
Corporate Officer/Principal | - | 96-12-31 | |
Kathryn Collins
LAW | General Counsel | - | 98-12-31 |
John McCoy
AUD | Comptroller/Controller/Auditor | 54 | 17-12-31 |
Hubert Allen
LAW | General Counsel | 58 | 05-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Starks
BRD | Director/Board Member | 69 | 17-02-15 |
John Stratton
BRD | Director/Board Member | 63 | 17-06-28 |
Nancy McKinstry
BRD | Director/Board Member | 65 | 11-12-08 |
Robert Alpern
BRD | Director/Board Member | 73 | 08-10-09 |
Michael Roman
BRD | Director/Board Member | 64 | 21-04-22 |
Michael O'Grady
BRD | Director/Board Member | 58 | 23-04-27 |
Robert Ford
CEO | Chief Executive Officer | 50 | 14-12-31 |
Sally Blount
BRD | Director/Board Member | 62 | 11-12-08 |
Michelle Kumbier
BRD | Director/Board Member | 57 | 18-06-07 |
Darren McDew
BRD | Director/Board Member | 63 | 19-09-08 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,989,789,999 | 1,730,390,898 ( 86.96 %) | 250,155,515 ( 12.57 %) | 86.96 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
ABBOTT INDIA LIMITED 74.99% | 15,934,048 | 74.99% | 5,280,606,925 $ |
76,259,451 | 77.90% | 200,850,617 $ | |
17,949,800 | 51.69% | 43,719,789 $ | |
ALLERGY THERAPEUTICS PLC 2.98% | 142,136,143 | 2.98% | 9,415,098 $ |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Medical Specialties
| |
Cozart Ltd.
Cozart Ltd. Medical SpecialtiesHealth Technology Cozart Ltd. designs and manufactures diagnostics products. Its products are used to test for the presence of various drugs of abuse, such as opiates, cocaine, amphetamine, methamphetamine and cannabis. The company also offers laboratory services providing screening and confirmation services in samples including oral fluid, urine, and blood. Cozart was founded by Dr. Christopher William Hand and Philip Hand in 1993 and is located in Abingdon, the United Kingdom. |
Medical Specialties
|
Abbott Toxicology Ltd.
Abbott Toxicology Ltd. Medical SpecialtiesHealth Technology Abbott Toxicology Ltd. provides drug and alcohol testing products and services. It offers advisory services and testing capabilities, including laboratory testings, point of care tests and sample types for any biological specimen, including urine, oral fluids, hair and sweat. The company was founded in 2005 and is headquartered in Abingdon, the United Kingdom. |
Medical Specialties
|
Pharmaceuticals: Major
| |
Abbott Established Products Holdings (Gibraltar) Ltd.
| |
Pharmaceuticals: Major
| |
Abbott GmbH (Germany)
Abbott GmbH (Germany) Pharmaceuticals: MajorHealth Technology Abbott GmbH & Co. KG develops and manufactures health care products. It is engaged in the discovery, development, manufacture, and marketing of pharmaceutical, diagnostic, nutritional, and hospital products. It offers pharmaceutical and diagnostic products ranging from prevention and diagnosis to treatment and cure. The company is headquartered in Ludwigshafen, Germany. |
Pharmaceuticals: Major
|
Laboratoires Fournier SAS
Laboratoires Fournier SAS Pharmaceuticals: MajorHealth Technology Laboratoires Fournier SAS manufactures pharmaceutical preparations. The company was founded on July 10, 2007 and is headquartered in Rungis, France. |
Pharmaceuticals: Major
|
Abbott Cardiovascular Systems, Inc.
Abbott Cardiovascular Systems, Inc. Medical SpecialtiesHealth Technology Abbott Cardiovascular Systems, Inc. manufactures medical devices. It also makes cardiac and peripheral vascular repair surgical systems. The company was founded in 1978 and is headquartered in Santa Clara, CA. |
Medical Specialties
|
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.72% | 98.53B | |
-7.50% | 65.18B | |
-10.57% | 44.13B | |
+8.92% | 44.05B | |
+14.33% | 42.51B | |
+9.65% | 28.41B | |
+22.13% | 25.31B | |
-9.13% | 23.31B | |
-12.58% | 21.89B |
- Stock Market
- Equities
- ABT Stock
- ABL Stock
- Company Abbott Laboratories